The development partners said they will share data with regulators, and AstraZeneca said it will harmonize its share listing across international stock exchanges.

The firms reported promising data from two trials of zipalertinib in patients who have received prior EGFR exon 20-directed therapy and those who haven't.

The funding will support the firm's pipeline of mRNA and gene correction therapies, including an investigational inhaled mRNA therapy under testing for cystic fibrosis.

Retrospective research from more than a decade ago demonstrated the potential benefit, but it hadn't been confirmed in a ...

In an increasingly crowded space, the firm is using streamlined manufacturing and lipid nanoparticle delivery for its in vivo ...

A real-world study showed that patients who had the classical subtype based on an RNA signature had better survival on ...

A team from Shriners Children's and Washington University in St. Louis are investigating a new method for personalizing ...

The agency held a meeting to gather drugmakers' perspectives as it considers a draft guidance on how previously generated ...

The firm commenced a $200 million underwritten public offering, secured $125 million in non-dilutive funding, and refinanced $50 million in debt.

The firm said it found its antibody-drug conjugate payload had activity as both a monotherapy and in combination with androgen receptor inhibitors.

The approval follows the CHMP's reversal of a previous decision not to recommend the drug, instead recommending it with certain restrictions.

Researchers still see potential for the TIL therapy to benefit patients if combined with other immunotherapies, like checkpoint inhibitors.